Red Bank, N.J. – August 7, 2025 — OrthoNu®, the first company solely focused on innovating self-care solutions for orthodontic patients, today announced a strategic partnership with Nualtis (formerly IntelGenx Corp.), a global leader in oral thin-film drug delivery technology. This collaboration marks a significant step forward in the development of OrthoNu's over-the-counter (OTC) oral care product line, designed to improve patient comfort, convenience, and clinical outcomes.
The partnership will integrate OrthoNu's patented technologies with Nualtis' proprietary film platform to bring to market a portfolio of dietary supplements and FDA OTC monograph-compliant products. These offerings will feature advanced timed-release profiles, delivering sustained and targeted oral health benefits to orthodontic patients.
"Partnering with Nualtis allows us to accelerate the delivery of our science-backed innovations. Their 15+ years of experience in thin-film development and manufacturing make them the ideal partner to help us redefine oral-systemic care for orthodontic patients."
"We are excited to collaborate with OrthoNu on products that have the potential to transform the orthodontic care landscape. This partnership represents a unique alignment of our technology with OrthoNu's groundbreaking vision."
Together, the companies will develop multiple product variants designed to enhance patient adherence and comfort during orthodontic treatment, while supporting providers with differentiated, innovative tools for in-office and take-home care.
About OrthoNu®
OrthoNu® is a category-defining oral wellness company founded by orthodontist-turned-entrepreneur Dr. Sima Yakoby Epstein. The company offers professional-grade, self-care products that support patient outcomes and practice efficiency. OrthoNu is committed to transforming the orthodontic experience through science-backed innovation and strategic collaboration.
OrthoNu LLC · 125 Half Mile Road, Suite 200 · Red Bank, New Jersey 07701 · www.orthonu.com
About Nualtis
Nualtis is a Montreal-based specialty pharmaceutical company and a wholly owned subsidiary of atai Life Sciences. The company specializes in oral thin-film delivery technologies, offering pharmaceutical partners fully integrated services from formulation to commercial manufacturing. With a focus on patient-centered innovation and execution excellence, Nualtis provides solutions that meet real-world therapeutic needs.
www.nualtis.com